BGM0504: A Next-Generation Dual GLP-1/GIP Peptide Designed to Outperform Tirzepatide | Research

The takeaway

Using molecular simulations, researchers redesigned tirzepatide to create BGM0504, a dual GLP-1/GIP agonist with 2-3x greater potency while keeping the same long-lasting action.

2-3x more potent
than tirzepatide at activating GLP-1 and GIP receptors, while maintaining the same long-lasting action

What the researchers found

BGM0504 achieved a 2-3 fold increase in agonistic activity at both GLP-1R and GIPR compared to tirzepatide, while maintaining equivalent extended plasma half-life, by repositioning the acylation side chain based on molecular dynamics insights.

Why it matters

Tirzepatide is already one of the most effective diabetes and obesity drugs available. A peptide that is 2-3x more potent could mean lower doses, fewer side effects, or greater efficacy — potentially advancing the next generation of metabolic disease treatment.

The numbers in context

BGM0504 was optimized using molecular dynamics to achieve enhanced dual-target agonism at both GLP-1R and GIPR.

How the study worked

Molecular dynamics simulations to map peptide-receptor interactions, followed by structure-guided peptide optimization. Validated with in vitro receptor activation assays and in vivo animal studies comparing BGM0504 to tirzepatide.

Who was studied

Computational molecular dynamics study of dual agonist peptide design

What this study cannot tell us

Preclinical data only — no human trials yet. In vitro and animal study results do not always translate to clinical superiority. The 2-3x potency increase in receptor activation may not produce proportionally better clinical outcomes. Safety profile in humans is unknown.

How to read the evidence

Preliminary evidence: computational design validated by in vitro and animal studies. No human clinical trial data yet.

When this study was published

Published in 2024. Represents cutting-edge peptide drug design using computational methods.

The bigger picture

The race to improve upon GLP-1 drugs is intensifying. BGM0504 represents a computational approach to peptide drug design — using molecular simulations to find optimizations that traditional methods might miss. If clinical trials confirm these preclinical results, it could become a more potent alternative to tirzepatide.

Questions still open

Will BGM0504 show meaningful clinical advantages over tirzepatide in human trials?
Does increased receptor potency translate to better weight loss and glycemic control, or just more side effects?
How does BGM0504 compare to other next-generation dual and triple agonist peptides in development?

Common questions

How is BGM0504 different from tirzepatide?

Both activate GLP-1 and GIP receptors, but BGM0504 has a repositioned chemical modification that allows 2-3 times stronger receptor activation without losing the long-lasting action. Think of it as the same key, resharpened to turn the lock more effectively.

When could BGM0504 become available?

It is currently in preclinical stages. If it advances to clinical trials and succeeds, it could be years before potential approval. However, its computational design approach may accelerate development compared to traditional drug discovery.

Read the original research

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.

Scientific reports, 14(1), 16680

View on PubMed ↗Publisher’s paper ↗

Citation

Yuan, Jiandong; Liu, Wenlang; Jiang, Xiaohui; Huang, Yangqing; Zong, Leilei; Ding, Haifeng; Shen, Xinyi; Sun, Yujia; Feng, Xiangyang; Li, Xionghao; Song, Yunsong; Gu, Jianing; Wang, Yuhuai; Liu, Hao; Zheng, Zheng. (2024). Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.. Scientific reports, 14(1), 16680. https://doi.org/10.1038/s41598-024-66998-8